VENTYX BIOSCIENCES INC (VTYX)
US92332V1070 - Common Stock
We assign a fundamental rating of 2 out of 10 to VTYX. VTYX was compared to 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for VTYX as it has an excellent financial health rating, but there are worries on the profitability. VTYX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
VTYX had negative earnings in the past year.
In the past year VTYX has reported a negative cash flow from operations.
In the past 5 years VTYX always reported negative net income.
VTYX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VTYX has a worse Return On Assets (-50.66%) than 62.83% of its industry peers.
VTYX has a Return On Equity of -54.71%. This is comparable to the rest of the industry: VTYX outperforms 54.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.66% | ||
| ROE | -54.71% | ||
| ROIC | N/A |
ROA(3y)-42.65%
ROA(5y)-3131.26%
ROE(3y)-46.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VTYX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for VTYX has been increased compared to 1 year ago.
There is no outstanding debt for VTYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VTYX has an Altman-Z score of 1.36. This is a bad value and indicates that VTYX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VTYX (1.36) is better than 61.26% of its industry peers.
There is no outstanding debt for VTYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.36 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 23.52 indicates that VTYX has no problem at all paying its short term obligations.
The Current ratio of VTYX (23.52) is better than 93.72% of its industry peers.
VTYX has a Quick Ratio of 23.52. This indicates that VTYX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 23.52, VTYX belongs to the best of the industry, outperforming 94.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 23.52 | ||
| Quick Ratio | 23.52 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 24.60% over the past year.
EPS 1Y (TTM)24.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 14.21% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.18%
EPS Next 2Y15.6%
EPS Next 3Y11.42%
EPS Next 5Y14.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VTYX. In the last year negative earnings were reported.
Also next year VTYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.6%
EPS Next 3Y11.42%
5. Dividend
5.1 Amount
VTYX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VENTYX BIOSCIENCES INC
NASDAQ:VTYX (12/27/2024, 8:00:02 PM)
After market: 2.38 0 (0%)2.38
+0.05 (+2.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners91.6%
Inst Owner Change-7.7%
Ins Owners2.88%
Ins Owner Change5.34%
Market Cap168.29M
Analysts80
Price Target11.37 (377.73%)
Short Float %12.66%
Short Ratio6.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.52%
Min EPS beat(2)5.28%
Max EPS beat(2)23.77%
EPS beat(4)4
Avg EPS beat(4)13.68%
Min EPS beat(4)5.28%
Max EPS beat(4)23.77%
EPS beat(8)5
Avg EPS beat(8)3.55%
EPS beat(12)8
Avg EPS beat(12)7.69%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.12%
PT rev (3m)11.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.88%
EPS NY rev (1m)0%
EPS NY rev (3m)2.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.6 | ||
| P/tB | 0.6 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.36
EYN/A
EPS(NY)-2.19
Fwd EYN/A
FCF(TTM)-2.26
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0
BVpS3.94
TBVpS3.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.66% | ||
| ROE | -54.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.65%
ROA(5y)-3131.26%
ROE(3y)-46.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 173.36% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 23.52 | ||
| Quick Ratio | 23.52 | ||
| Altman-Z | 1.36 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)475.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.65%
EPS Next Y35.18%
EPS Next 2Y15.6%
EPS Next 3Y11.42%
EPS Next 5Y14.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.03%
EBIT Next 3Y4.37%
EBIT Next 5YN/A
FCF growth 1Y-140.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.56%
OCF growth 3YN/A
OCF growth 5YN/A